Company news

Novo Nordisk A/S news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Metsera Receives Unsolicited Proposal from Novo Nordisk

October 30, 2025

Novo Nordisk submits proposal to acquire Metsera, Inc.

October 30, 2025

Novo Nordisk to present new Wegovy® (semaglutide 2.4 mg) data at the 2025 American Association for the Study of Liver Diseases annual meeting

October 28, 2025

Novo Holdings to make changes to its Board of Directors

October 21, 2025

The Novo Nordisk Foundation proposes new candidates for election as members of the Board of Directors of Novo Nordisk A/S

October 21, 2025

Notice convening an Extraordinary General Meeting of Novo Nordisk A/S

October 21, 2025

Novo Nordisk announces an Extraordinary General Meeting to be convened to elect new members of the Board of Directors

October 21, 2025

Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025

October 20, 2025

FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event

October 17, 2025

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

October 15, 2025

Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio

October 9, 2025

Novo Nordisk resubmits Awiqli® to the FDA with potential to be the first once-weekly basal insulin treatment for adults with type 2 diabetes

September 29, 2025

Novo Nordisk submits Biologics License Application (BLA) to FDA for Mim8; an investigational, prophylaxis treatment for people living with hemophilia A with or without inhibitors

September 29, 2025

← Newer news releases

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 230 decks. Every deck is listed under its year.